Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases

BioFactors

Volumn 9, Issue 2-4, 1999, Pages 261-266

  Beal, M Flint ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UBIDECARENONE; ANTIOXIDANT; DRUG DERIVATIVE; LACTIC ACID DERIVATIVE; UBIQUINONE;

ANTIOXIDANT ACTIVITY; ARTICLE; DEGENERATIVE DISEASE; DRUG EFFECT; DRUG SCREENING; HUMAN; HUNTINGTON CHOREA; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; RESPIRATORY CHAIN; TRANSGENIC MOUSE; ANIMAL; BLOOD; MOUSE; REVIEW;

ANIMALIA; MUS MUSCULUS;

ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; HUMANS; HUNTINGTON DISEASE; LACTATES; MICE; MICE, TRANSGENIC; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; UBIQUINONE;

EID: 0032588769     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.5520090222     Document Type: Article

References (39)

1. A. Favit, F. Nicoletti, U. Scapagnini and P.L. Canonico, Ubiquinone protects cultured neurons against spontaneous and excitotoxin-induced degeneration, J. Cereb. Blood Flow Metab. 12 (1992), 638-645.
2. A. Kalen, E.-L. Appelkvist and G. Dallner, Age-related changes in the lipid compositions of rat and human tissues, Lipids 24 (1989), 579-584.
3. B. Jenkins, W. Koroshetz, M.F. Beal and B. Rosen, Evidence for an energy metabolism defect in Huntington's disease using localized proton spectroscopy, Neurology 43 (1993), 2689-2695.
4. 1H NMR spectroscopy in Huntington's. Striatal asymmetries and correlations with CAG repeats, Neurology 50 (1998), 1357-1365.
5. C. Edlund, K. Holmberg, G. Dallner, E. Norrby and K. Kristensson, Ubiquinone-10 protects neurons from virus-induced degeneration, J. Neurochem. 63 (1994), 634-639.
6. C. Muscari, L. Biagetti, C. Stefanelli, E. Giordano, C. Guarnieri and C.M. Caldarera, Adaptive changes in coenzyme Q biosynthesis to myocardial reperfusion in young and aged rats, J. Mol. Cell. Cardiol. 27 (1995), 283-289.
7. C.P. Earnest, A.L. Almada and T.L. Mitchell, High-performance capillary electrophoresis-pure creatine monohydrate reduces blood lipids in men and women, Clin. Sci. 91 (1996), 113-118.
8. 10 in parkinsonian patients, Neurology 50 (1998), 793-795.
9. 10 is reduced in mitochondria from parkinsonian patients, Ann. Neurol. 42 (1997), 261-264.
10. D.R. Rosen, T. Siddique, D. Patterson, D.A. Figiewicz, P. Sapp and A. Hentati, Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis, Nature 362 (1993), 59-62.
11. 10, Neurosci. Lett. 177 (1994), 58-62.
12. E. Brouillet, P. Hantraye, R.J. Ferrante, R. Dolan, A. Leroy-Willig, N.W. Kowall and M.F. Beal, Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates, Proc. Natl. Acad. Sci. USA 92 (1995), 7105-7109.
13. H. Noack, U. Kube and W. Augustin, Relations between tocopherol depletion and coenzyme Q during lipid peroxidation in rat liver mitochondria, Free Radic. Res. 20 (1994), 375-386.
14. J. Kong and Z. Xu, Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1, J. Neurosci. 18 (1998), 3241-3250.
15. J.-R. Zhang, H.M. Scherch and E.D. Hall, Direct measurement of lipid hydroperoxides in iron-dependent spinal neuronal injury, J. Neurochem. 66 (1996), 355-361.
16. J.B. Schulz, D.R. Henshaw, D. Siwek, B.G. Jenkins, R.J. Ferrante, P.B. Cipolloni, N.W. Kowall, B.R. Rosen and M.F. Beal, Involvement of free radicals in excitotoxicity in vivo, J. Neurochem. 64 (1995), 2239-2247.
17. J.B. Schulz, R.T. Matthews, D.R. Henshaw and M.F. Beal, Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases, Neuroscience 71 (1996), 1043-1048.
18. K. Abe, H. Fujimura, Y. Nishikawa, S. Yorifuki, T. Mezaki, N. Hirono, N. Nishitani and M. Kameyama, Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS), Acta Neurol. Scand. 83 (1991), 356-359.
19. L. Landi, D. Fiorentini, M.C. Galli, J. Segura-Aguilar and R.E. Beyer, DT-diaphorase maintains the reduced state of ubiquinones in lipid vesicles thereby promoting their antioxidant function, Free Radic. Biol. Med. 22 (1997), 329-335.
20. M. Battino, A. Gorini, R.F. Villa, M.L. Genova, C. Bovina, S. Sassi, G.P. Littarru and G. Lenaz, Coenzyme Q content in synaptic and non-synaptic mitochondria from different brain regions in the ageing rat, Mech. Ageing Develop. 78 (1995), 173-187.
21. M.E. Gurney, H. Pu, A.Y. Chiu, M.C. Dal Canto, C.Y. Polchow, D.D. Alexander, J. Caliendo, A. Hentati, Y.W. Kwon, H.-X. Deng, W. Chen, P. Zhai, R.L. Sufit and T. Siddique, Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation, Science 264 (1994), 1772-1775.
22. M.F. Beal, Aging, energy and oxidative stress in neurodegenerative diseases, Ann. Neurol. 38 (1995), 357-366.
23. 10 in the central nervous system and its potential usefulness in the treatment of neurodegenerative diseases, Molec. Aspects Med. 18 (1997), s169-s179.
24. M.F. Beal, E. Brouillet, B.G. Jenkins, R.J. Ferrante, N.W. Kowall, J.M. Miller, E. Storey, R. Srivastava, B.R. Rosen and B. Hyman, Neurochemical and histologic characterization of excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid, J. Neurosci. 13 (1993), 4181-4191.
25. 10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate, Ann. Neurol. 36 (1994), 882-888.
26. 10 attenuates the MPTP induced loss of striatal dopamine and dopaminergic axons in aged mice, Brain Res. 783 (1997), 109-114.
27. 10, Neurology 38 (1988), 892-899.
28. P. Forsmark-Andree, C.-P. Lee, G. Dallner and L. Ernster, Lipid peroxidation and changes in the ubiquinone content and the respiratory chain enzymes of submitochondrial particles, Free Radic. Biol. Med. 22 (1997), 391-400.
29. P.C. Wong, C.A. Pardo, D.R. Borchelt, M.K. Lee, N.G. Copeland, N.A. Jenkins, S.S. Sisodia, D.W. Cleveland and D.L. Price, An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria, Neuron 14 (1995), 1105-1116.
30. R.E. Beyer, An analysis of the role of coenzyme Q in free radical generation and as an antioxidant, Biochem. Cell. Biol. 70 (1992), 390-403.
31. R.E. Beyer, B.-A. Burnett, K.J. Cartwright, D.E. Edington, M.J. Falzon, K.R. Kreitman, T.W. Kuhn, B.J. Ramp, S.Y.S. Rhee, M.J. Rosenwasser, M. Stein and L.C.-I. An, Tissue coenzyme Q (ubiquinone) and protein concentrations over the life span of the laboratory rat, Mech. Ageing Develop. 32 (1985), 267-281.
32. R.J. Ferrante, L.A. Shinobu, J.B. Schulz, R.T. Matthews, C.E. Thomas, N.W. Kowall, M.E. Gurney and M.F. Beal, Increased 3-nitrotyrosine and oxidative damage in mice with a human Cu, Zn superoxide dismutase mutation, Ann. Neurol. 42 (1997), 326-334.
33. 10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects, Proc. Natl. Acad. Sci. USA (1998) (in press).
34. 10 in the rat following its oral and intraperitoneal administration, Drug Metab. Dispos. 20 (1992), 423-427.
35. T.Q. Do, J.R. Schultz and C.F. Clarke, Enhanced sensitivity of ubiquinone-deficient mutants of Saccharomyces cerevisiae to products of autoxidized polyunsaturated fatty acids, Proc. Natl. Acad. Sci. USA 93 (1996), 7534-7539.
36. 10, Ann. Neurol. 41 (1997), 160-165.
37. 10 and idebenone, J. Neurol. Sci. 90 (1989), 263-271.
38. 31P NMR study, Neurology 39 (1989), 399-403.
39. Y. Zhang, F. Aberg, E.-L. Appelkvist, G. Dallner and L. Ernster, Uptake of dietary coenzyme Q supplement is limited in rats, J. Nutr. 125 (1995), 446-453.